Loading...
Liraglutide is the only glucagon-like peptide-1 (GLP-1) agonist that is approved for weight management (under the brand name Saxenda) in patients without diabetes (NEJM JW Gen Med Aug 1 2015 and N Engl J Med 2015; 373:11). In this industry-supported trial, researchers examined the drug's effect in combination with diet and exercise.
The trial included adults with obesity (body-mass index, 32–43 kg/m2; mean BMI, 37 kg/m2) who were enrolled in an 8-week, low-calorie diet program (800 kcal daily). The 195 people who lost ≥5% of their body weight during this run-in phase were then randomized to one of four groups: usual activity plus placebo (placebo group); intensive aerobic exercise program plus placebo (exercise group); usual activity plus li…